TRPV1 and bone cancer: It has been suggested that the PD‐L1/PD‐1 signaling pathway can exert analgesic effects on bone cancer pain in mice by inhibiting TRPV1 activity in primary sensory neurons via SHP‐1 to delay pain or by suppressing PD‐L1/CCl2‐mediated osteoclastogenesis and protecting against bone destruction.24, 31